The Upward Trend
BIOLASE, Inc. shares, under ticker symbol BIOL on the NASDAQ, are on an upswing following the company’s fourth-quarter FY23 earnings report exceeding expectations.
Revenue and Profits
The company reported revenues of $13.49 million, slightly below the consensus of $13.55 million. However, gross profit at $3.52 million, compared to $3.60 million the previous year, demonstrated positive growth.
Strong Performance
EPS loss of $(1.76) outperformed the anticipated $(2.56), indicating a strong performance in earnings per share.
Financial Health
BIOLASE’s cash and cash equivalents as of December 31, 2023, stood at a solid $6.57 million, underpinning the company’s financial stability.
Strategic Vision
John Beaver, President and CEO of BIOLASE, highlighted the company’s goal to accelerate growth driven by increased utilization of their products, such as a notable 20% rise in consumable sales during the year.
Forward-Looking Statements
BIOLASE projects first-quarter net revenue to surpass $10.0 million and expects flat year-over-year growth. For FY24, the company foresees a 6% to 8% Y/Y revenue increase to $52 million – $53 million, with positive adjusted EBITDA outcomes.
Market Adoption
The optimistic outlook is based on the continuous adoption of BIOLASE’s lasers and consumables by various dental professionals and entities in the dental community.
Investment Opportunities
Investors looking to capitalize on BIOLASE’s success can consider exposure through Vanguard Extended Market ETF under the ticker VXF on the NYSE.
Share Performance
BIOLASE’s stock is showing a significant rise of 28% and is currently trading at $0.1922 as of the latest check on Friday.
Photo via Shutterstock
